The mission of the ITN is the development of
new immune tolerance therapies — highly specific treatments that reprogram the immune system to inhibit disease - causing immune responses while keeping beneficial, disease - fighting immune responses intact.
Not exact matches
One gene that controls this pathway, HDAC7, is known to be a key factor in
immune tolerance and the
new data strongly suggests exploring the possibility that drugs affecting HDAC7 function may serve as future therapeutics in PSC.
In the
new study, scientists built upon previous discoveries that a safe, non-reproducing vaccine strain of T. gondii could cure mice of several types of solid tumors, and identified which parasite proteins and which immunological pathways are required to break
immune tolerance.
«
New key regulator of acquisition of
immune tolerance to tumor cells in cancer patients.»